The Lancet Neuropeptide Research: Semax, Selank, and Nootropic Peptides for Cognitive Function

Lancet Insights | 2026-07-03 | 11 min read

Analysis of Russian neuropeptides Semax and Selank, covering ACTH fragments, BDNF modulation, anxiety research, and cognitive enhancement mechanisms for neurological research.

Nootropic Peptides: Semax and Selank Research

The Lancet has covered neuropeptide research extensively, particularly regarding cognitive function, anxiety disorders, and neurological protection. Russian-developed neuropeptides Semax and Selank represent an important class of nootropic peptides with established clinical use and ongoing research interest. This analysis examines their mechanisms, clinical applications, and research applications.

Semax: ACTH Fragment Analogue

Discovery and Structure

Semax was developed at the Institute of Molecular Genetics in Moscow:

Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (ACTH fragment 4-10) + D Lys + Pro

Modifications:

• ACTH(4-10) core sequence
• Added D-lysine for enhanced activity
• Glycine-proline for stability

Mechanism of Action

Semax operates through multiple CNS pathways:

#### Melanocortin Receptors

• MC1-MC5 receptors expressed in brain
• ACTH(4-10) fragment has highest affinity
• Modulates neurotransmitter release
• Affects memory and attention

#### BDNF Modulation

Semax increases brain-derived neurotrophic factor:

• Upregulates BDNF mRNA expression
• Promotes neuronal survival
• Enhances synaptic plasticity
• Supports memory consolidation

#### Neurotransmitter Effects

• Dopamine system modulation
• Serotonin metabolism effects
• Cholinergic activity enhancement
• Balance of excitatory/inhibitory transmission

Clinical Applications

Semax is approved in Russia for:

#### Cognitive Disorders

• Memory impairment
• Attention deficits
• Post-stroke cognitive dysfunction
• Age-related cognitive decline

#### Neurological Protection

• Ischemic stroke recovery
• Traumatic brain injury
• Neurodegenerative disease support
• Cognitive protection during stress

Research Evidence

Clinical studies in Russian literature:

• Improved memory in various populations
• Accelerated stroke recovery
• Reduced anxiety in clinical trials
• Generally well-tolerated

Selank: Tuftsin-GABA Analogue

Structure and Development

Selank was developed combining two sequences:

Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (tuftsin fragment) + GABA + Glycine-Proline

Components:

• Tuftsin: Immunomodulatory tetrapeptide
• GABA: Primary inhibitory neurotransmitter
• Gly-Pro: Dipeptide for stability

Mechanism of Action

Selank affects multiple neurotransmitter systems:

#### GABAergic Effects

• Modulates GABA-A receptors
• Anxiolytic (anti-anxiety) properties
• Reduces anxiety without sedation
• May affect GABA transaminase

#### Enkephalin Modulation

• Affects enkephalin degradation
• Modulates endogenous opioid activity
• Contributes to anxiolytic effects
• Non-addictive mechanism

#### Cytokine Modulation

• Affects IL-1β, IL-6, TNF-α
• Anti-inflammatory properties
• Supports immune-brain communication
• Potential neuroprotective effects

Clinical Applications

Selank is approved in Russia for:

#### Anxiety Disorders

• Generalised anxiety
• Anxiety-phobic conditions
• Adjustment disorders
• Post-traumatic stress

#### Cognitive Support

• Combined anxiety-cognitive effects
• Adjunctive cognitive therapy
• Stress-related cognitive impairment

Research Evidence

Clinical studies demonstrate:

• Significant anxiety reduction vs placebo
• No sedation or dependence
• Improved cognitive function
• Favourable safety profile

Comparative Analysis

Semax vs Selank

| Property | Semax | Selank | |----------|-------|--------| | Primary effect | Cognitive enhancement | Anxiolytic | | Mechanism | Melanocortin, BDNF | GABAergic, enkephalin | | Approved use | Cognitive disorders | Anxiety disorders | | Research focus | Memory, stroke | Anxiety, cognitive | | Typical dosing | Intranasal | Intranasal/sublingual |

Combination Potential

Research explores combined use:

• Addressing anxiety and cognitive dysfunction together
• Complementary mechanisms
• Potential synergistic effects
• Both approved and well-tolerated

Research Applications

Cognitive Research

Semax and Selank in cognitive studies:

• Memory consolidation paradigms
• Attention and learning tasks
• Neuroplasticity markers
• BDNF measurement
• Neuroimaging studies

Anxiety Research

Selank anxiety research:

• Animal anxiety models
• Human anxiety scales
• Stress hormone measurement
• HPA axis function
• Neuroimaging of anxiety circuits

Neuroprotection Research

Stroke and TBI applications:

• Ischemia-reperfusion models
• Inflammatory markers
• Neuronal survival
• Functional recovery assessment

Quality Standards

Purity Requirements

Neuropeptide research requires:

• HPLC purity ≥99.5%
• Mass spectrometry verification
• D-amino acid configuration confirmation
• Endotoxin testing for intranasal
• Batch-specific COA documentation

Formulation Considerations

Intranasal delivery research:

• Appropriate buffer systems
• pH optimisation for nasal mucosa
• Permeation enhancers
• Stability data

Future Directions

Extended Research

Areas needing further study:

• Western clinical trial data
• Long-term safety in humans
• Mechanism elucidation
• Combination with other therapies

Novel Nootropic Peptides

Emerging neuropeptide research:

• Dihexa (AT2 agonist)
• Cerebrolysin
• Noopept
• Semax analogues

Dosage Research

Reported Dosing

Research protocols report:

Semax:

• Intranasal: 1-3 drops per nostril
• 2-3 times daily
• Typical dose: 0.5-1 mg/day

Selank:

• Intranasal: 2-3 drops per nostril
• 2-3 times daily
• Typical dose: 0.5-1 mg/day

Concentration Ranges

Research concentrations:

• In vitro: 0.01-10 μM
• Intranasal: 0.1-1% solutions
• In vivo: 10-100 μg/kg

ZePeptide provides research-grade Semax, Selank, and nootropic peptides with complete analytical documentation for neuroscience research.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.